Edgewise Therapeutics Q1 net loss widens on higher R&D costs

Edgewise Therapeutics

07/05/2026 13:11

Overview

U.S. muscle disease biopharma reported Q1 net loss widened to $49 mln from prior year

Operating expenses rose on increased clinical development and higher personnel costs

Result Drivers

R&D SPENDING - Higher research and development costs driven by increased clinical activity for EDG-7500 and EDG-15400

ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher personnel costs, stock-based compensation, and increased professional fees

Company press release: ID:nPnb6ky4Ta

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$49.01 mln
Q1 Basic EPS
-$0.46


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Edgewise Therapeutics Inc is $46.00, about 24.4% above its May 6 closing price of $36.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)